TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo - Test2 - elhamkhani - TriplyDB

TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo

TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo

http://www.wikidata.org/entity/Q34256933

about

Pronounced peptide selectivity for melanoma through tryptophan end-tagging Replication Study: Discovery and preclinical validation of drug indications using compendia of public gene expression data Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors Two hits are better than one: synergistic anticancer activity of α-helical peptides and doxorubicin/epirubicin Verticillin A overcomes apoptosis resistance in human colon carcinoma through DNA methylation-dependent upregulation of BNIP3.Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer.Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models How to target apoptosis signaling pathways for the treatment of pediatric cancers Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin Guiding TRAIL to cancer cells through Kv10.1 potassium channel overcomes resistance to doxorubicin.Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes.Resistance to TRAIL and how to surmount it.Non-invasive molecular imaging for preclinical cancer therapeutic development.The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy.A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth.PTEN and TRAIL genes loaded zein nanoparticles as potential therapy for hepatocellular carcinoma.Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.Lipid Nanoparticles Decorated with TNF-Related Aptosis-Inducing Ligand (TRAIL) Are More Cytotoxic than Soluble Recombinant TRAIL in Sarcoma.

P2860

Q27318810-82EE819E-B020-4769-AD4B-7FFF266B2849 Q28559693-4656188E-1E63-45FD-91C0-49A71AEE15BC Q28559700-D3478D7B-6152-4A8F-97A7-D2B1DCC42670 Q35028802-990A1D15-CF75-4D8F-A1AA-0E5A83A41D75 Q35053276-C3878FDA-218A-49B4-9345-143D8A6E3391 Q35176436-FD36D873-9C7D-4B3A-9A13-818A5B4B54FF Q35501202-241A58A5-132C-4D18-862B-0A4A1F7370E3 Q35972500-C3F68239-E656-4412-903F-5AE0944A24A9 Q36342896-934BFB49-1386-4A0D-973E-588402B022E6 Q36610528-68CC7857-840D-4DA2-A0B5-8B1D1B79C236 Q37061007-12175A56-7906-4662-997D-33AC82689094 Q37302038-18E341BA-D85F-4665-893D-4BAF3AB984DC Q37704467-2FE6D7CA-4085-409A-9D5C-91FF80B160E1 Q37992546-DF3B37F3-9770-4D8F-A2EF-55D06FD17301 Q38089102-68D74E5B-1B74-457B-BD4A-79A892EC504F Q38437281-1CCA7C66-3000-4977-954F-3072C621F6E4 Q39311514-482E2344-202E-434D-B621-514AB9B30232 Q45864098-85004381-71DB-452C-BBBC-E7B93652444C Q45874985-752DA3CF-8E96-49AA-A529-6A0ED3F934A9 Q53682889-890E8088-C458-4390-B72F-5B65676DB667

P2860

TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo

http://www.wikidata.org/entity/Q34256933

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

TRAIL and doxorubicin combinat ...... in soft tissue sarcoma in vivo

@ast

TRAIL and doxorubicin combinat ...... in soft tissue sarcoma in vivo

@en

TRAIL and doxorubicin combinat ...... in soft tissue sarcoma in vivo

@nl

type

label

TRAIL and doxorubicin combinat ...... in soft tissue sarcoma in vivo

@ast

TRAIL and doxorubicin combinat ...... in soft tissue sarcoma in vivo

@en

TRAIL and doxorubicin combinat ...... in soft tissue sarcoma in vivo

@nl

prefLabel

TRAIL and doxorubicin combinat ...... in soft tissue sarcoma in vivo

@ast

TRAIL and doxorubicin combinat ...... in soft tissue sarcoma in vivo

@en

TRAIL and doxorubicin combinat ...... in soft tissue sarcoma in vivo

@nl

P1433

Q34256933-9CB70431-12E2-47D3-958D-D2F5623E009F

P1476

Q34256933-AD80C5FF-218F-427B-ACE4-9DCA0FEF828B

P2093

Q34256933-1362E1FC-14FA-488F-B274-B1CC96280CB6

Q34256933-3F54EB0F-9B8E-4CC9-9045-4038CDDF5A91

Q34256933-89625AA5-A5B8-4BC3-807C-96907E7F0073

Q34256933-97212E00-CB15-4B3F-BAFF-F2EDC073B138

Q34256933-A536B169-FA62-4107-8AC3-0FF7A33AC149

Q34256933-BE68CAD5-BC19-4DF2-B2B6-AF8F3B90B10C

Q34256933-D51E7684-C326-429B-B177-61D8D6D2147B

Q34256933-D704499F-1214-43D0-8402-5FA2C9459112

Q34256933-F29E9D28-169F-4441-9C92-8DED53F8D95A

Q34256933-FB88D264-8E0C-416F-ADEF-67AC3ADA6698

P2860

Q34256933-0169B128-3097-42F3-8358-A6ACDD9A92A7

Q34256933-01F6345A-D9C5-4839-B55C-F44F61A1B7E8

Q34256933-02CD397C-B4B2-4977-93A6-534FCB083A2A

Q34256933-0D5251A5-4239-49DB-8383-18833B866DAD

Q34256933-18A8DCFE-89A7-4C69-A05A-7B709F99F314

Q34256933-2B1E8BA1-2113-4C24-806A-CAD9BA90710E

Q34256933-3068F59B-4DA0-4E91-82A6-E8D9A6317D8D

Q34256933-32E03721-0A23-447A-944F-34C4244D871B

Q34256933-543B80AE-E340-4304-863A-9455777FFD50

Q34256933-68FF7661-115D-40C2-9C96-921829749F4E

P304

Q34256933-9DB85B42-B19E-4F37-855F-9B2358D3C5BA

P31

Q34256933-499533D7-41AC-4F25-AFC5-9AC0B0028E55

P356

Q34256933-6ABC04EE-94E4-48B9-991D-9B70B528EC11

P407

Q34256933-52F6CE36-0F4A-4335-8F4D-18A1FB92881B

P433

Q34256933-DF4CD592-0958-4529-8A3F-F2A1835173E4

P478

Q34256933-00FA7C3B-C838-4EBC-8C27-9C033D53307A

P50

Q34256933-7CC68A65-BADC-4365-9D77-AC1E5108D0ED

Q34256933-91F74499-7AF8-4B8B-855F-B2EE9F6D2BF9

Q34256933-BC7425BE-A7F6-43F4-8EEE-FD7616DB05DF

P577

Q34256933-CDCFAF2C-FA06-40E0-8424-94259F712E95

P5875

Q34256933-EE03436C-C496-4001-9F74-01504A383F55

P698

Q34256933-E4F032C2-DA2D-434A-87D8-CDA024BEB7FC

P932

Q34256933-0B54A3F7-5D12-4A38-8904-111D975AB738

P356

1078-0432.CCR-09-2443

P1433

Clinical Cancer Research

P1476

TRAIL and doxorubicin combinat ...... in soft tissue sarcoma in vivo

@en

P2093

Andrea Hayes-Jordan

http://www.w3.org/2001/XMLSchema#string

Dina Lev

http://www.w3.org/2001/XMLSchema#string

Gonzalo Lopez

http://www.w3.org/2001/XMLSchema#string

Guy Lahat

http://www.w3.org/2001/XMLSchema#string

Jeffery Liu

http://www.w3.org/2001/XMLSchema#string

Jim Bankson

http://www.w3.org/2001/XMLSchema#string

John D Hazle

http://www.w3.org/2001/XMLSchema#string

Keila Torres

http://www.w3.org/2001/XMLSchema#string

Suizhao Wang

http://www.w3.org/2001/XMLSchema#string

Wenhong Ren

http://www.w3.org/2001/XMLSchema#string

P2860

Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5

Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma

IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

Safety and antitumor activity of recombinant soluble Apo2 ligand.

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

Management of soft-tissue sarcomas: an overview and update.

IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis.

Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand.

Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma.

P304

2591-2604

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-2443

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Alexander J. Lazar

Andrea Hayes-Jordan

P577

2010-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43226776

http://www.w3.org/2001/XMLSchema#string

P698

20406839

http://www.w3.org/2001/XMLSchema#string

P932

2967255

http://www.w3.org/2001/XMLSchema#string